22 results about "Cyclic adenosine monophosphate" patented technology

The invention discloses a construction method of an escherichia coli mutant for producing succinic acid by fermentation of a synthetic medium. The method comprises the following steps: firstly, knocking out a lactic dehydrogenase gene ldhA, a pyruvate formate lyase gene pflB, a ptsG gene responsible for encoding a phosphotransferase system EIIBC protein, an ethanol dehydrogenase gene adhE, an acetokinase-phosphate transacetylase gene ackA-pta, and a ptsG gene responsible for encoding a phosphotransferase system EIIBC protein in escherichia coli; a phosphoenolpyruvate carboxykinase gene pck from bacillus subtilis is integrated at an SS9 safety site of a strain to obtain escherichia coli ESC6 with high succinic acid yield; and mutating one or more loci in one or more genes of a glucose-transcriptional inhibition factor gene mlc, a nitrate response regulatory factor gene narL and a cyclic adenylate receptor protein gene crp to obtain the escherichia coli mutant capable of producing succinic acid by fermentation of a synthetic culture medium, wherein the one or more loci in one or more genes of the glucose-transcriptional inhibition factor gene mlc, the nitrate response regulatory factor gene narL and the cyclic adenylate receptor protein gene crp are mutated. The strain can be fermented in a synthetic medium to produce succinic acid, so that the fermentation cost is greatly reduced, and the strain has a very wide application prospect.

The invention relates to preparation of a cyclic adenosine monophosphate (cAMP) detection kit by using a chemiluminescence immunoassay technology. Cyclic adenosine monophosphate is an important second messenger for cell signal transduction and has wide physiological functions. Cyclic adenosine monophosphate is small in molecular weight and poor in immunogenicity, so that when a corresponding antibody is prepared, a proper derivative site needs to be selected firstly, and a derived hapten is coupled with a specific macromolecular carrier to prepare a complete antigen. According to the invention, the antibody with good specificity and strong affinity is successfully prepared by designing and transforming the hapten. The invention mainly relates to design and synthesis of a cyclic adenosine monophosphate hapten, preparation of a cyclic adenosine monophosphate complete antigen and an anti-cyclic adenosine monophosphate antibody, a method for measuring the concentration of cyclic adenosine monophosphate, and composition and components of a reagent. The design and synthesis of the hapten mainly comprise design and chemical synthesis of a cyclic adenylate derivative. The cyclic adenylic acid derivative disclosed by the invention has a structure as shown in a formula (I) which is described in the specification.

The invention provides a beta-galactosidase compound and a method. The beta-galactosidase compound comprises beta-galactosidase and cyclic adenosine monophosphate combined with amino acid residues of the beta-galactosidase. According to the invention, small molecular cyclic adenosine monophosphate acts on lactase molecules, and the catalytic activity of lactase is significantly enhanced through unique intermolecular interaction. Compared with a traditional lifting means, the method has the advantages that the lifting efficiency is higher, an ideal lactase activity level can be achieved in a shorter time, and a powerful guarantee is provided for lactose digestion and utilization.

The invention relates to a traditional Chinese medicine composition for treating ischemic heart failure and a preparation method thereof, and belongs to the field of traditional Chinese medicine pharmacy, and the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 5-15 parts of cassia twig, 5-15 parts of bighead atractylodes rhizome, 5-15 parts of poria cocos, 6-12 parts of rhizoma zingiberis, 5-15 parts of acanthopanax, 10-30 parts of fructus polygoni orientalis, 3-9 parts of verbena, 6-12 parts of dogwood and 3-9 parts of honey-fried licorice root. The composition can remarkably reduce the level of N-terminal proB-type natriuretic peptide, remarkably improve pathological changes of heart tissues of model rats, regulate and control the heart functions of the model rats, improve the systolic function of the heart, relieve expression of inflammatory factors such as interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha of the rats and improve the anti-inflammatory effect of the rats. The action mechanism of the compound relates to a plurality of pathways such as extracellular matrix receptor interaction, a chemotactic factor signal pathway, a relaxin signal pathway, a cyclic adenosine monophosphate signal pathway, a nuclear factor-kB signal pathway, fatty acid metabolism and a Toll-like receptor signal pathway, and the compound is an effective medicament for treating ischemic heart failure.

The application of a drug or medical aesthetic product containing tolvaptan as an active ingredient for inhibiting melanin synthesis. Cell activity detection and melanin content determination show that tolvaptan can significantly reduce the intracellular melanin content without affecting the cell activity. Tyrosinase activity detection shows that tolvaptan does not affect the catalytic activity of TYR. Western blotting experiment shows that tolvaptan can down-regulate the expression levels of TYR family proteins, microphthalmia-associated transcription factor (MITF), cyclic adenosine monophosphate response element binding protein (CREB) and melanocortin 1 receptor (MC1R).

The invention relates to the technical field of prediction models, and particularly discloses a pain and rheumatism syndrome biomarker, a diagnosis / prediction model and a construction method thereof. The pain and rheumatism syndrome biomarker comprises at least one of acetyl vanillin, cyclic adenosine monophosphate, methyl vanillate and uridine succinic acid; the pain and rheumatism syndrome biomarker comprises a pain and rheumatism syndrome diagnosis marker and a pain and rheumatism syndrome recurrence prediction marker; the pain and rheumatism syndrome diagnosis marker comprises at least one of acetyl vanillin, cyclic adenosine monophosphate and methyl vanillate; the pain and rheumatism syndrome recurrence prediction marker comprises cyclic adenosine monophosphate and uridine succinic acid. According to the application, a diagnosis model of the pain and rheumatism syndrome can be constructed on the basis of the expression levels of the three plasma metabolites, namely the acetylvanillin, the cyclic adenosine monophosphate and the methyl vanillate; based on the plasma expression level of cyclic adenosine monophosphate and uridine succinic acid, a gout recurrence prediction model can be developed, and high prediction accuracy is achieved.

Nucleic acid molecules comprising a first sequence encoding a cyclic nucleotide gated potassium channel or a functional fragment thereof and a second sequence encoding a chemogenetically activatable cyclic adenosine monophosphate (cAMP) generating receptor or a functional fragment thereof are provided. Expression vectors comprising the molecules, fusion proteins encoded by the molecules, cells, kits and pharmaceutical compositions are also provided. Methods of hyperpolarizing a cell, depolarizing a cardiac cell and treating a disease or condition are also provided.

The application discloses a kind of serum-free epidermal melanocyte culture medium and its application, method includes by dissolving adenine, hepatocyte growth factor (HGF), glutamine, retinoic acid, vitamin E, nicotinic acid, sodium selenite, sodium hyaluronate and recombination human type XVII collagen are configured into initial culture medium;Preparation of melanocyte stimulating hormone, endothelin-3, transferrin, triiodothyronine, cholesterol, neuroregulin 1 (NRG1), 3-isobutyl-1-methyl purine (IBMX), dibutyryl cyclic adenosine monophosphate (db-cAMP), cholera toxin, hydrocortisone and recombination human insulin mother liquor;Step three: according to culture and concentration, a certain amount of mother liquor of step two is added to initial culture medium.The culture medium can effectively promote human epidermal melanocyte proliferation, melanin accumulation and help to promote human umbilical cord mesenchymal stem cells into human epidermal melanocyte, provide key advantage for obtaining functional melanocyte with high activity and therapeutic potential.

The invention relates to an application of kunbutton alcohol as an active ingredient in preparation of a medicine or a medical beauty product for inhibiting melanin synthesis. Cell activity detection and melanin content determination show that the content of melanin in cells can be remarkably reduced under the condition of not influencing the cell activity. Tyrosinase activity detection shows that tolvaptan does not affect the catalytic activity of TYR. Protein immunoblotting experiments show that tolvaptan can down-regulate the expression levels of TYR family proteins, ommatidium-associated transcription factors (MITF), cyclic adenylate reaction element binding proteins (CREB) and melanocortin-1 receptors (MC1R).

The invention belongs to the technical field of medicinal and edible foods, and discloses an application of a red date extract containing cyclic adenosine monophosphate in preparation of a food for improving premature ovarian failure. The high-content cAMP in the red date extract is used as a core efficacy carrier, and animal experiments prove that the cAMP can accurately act on the pathologic link of premature ovarian failure. The limitation of single conditioning is broken through, and the dual effects of ovarian function improvement and qi and blood conditioning are achieved. The cAMP in the red date extract is combined with the nourishing effects of the Chinese wolfberry fruits, the rhizoma polygonati and the like, so that the premature ovarian failure can be improved in a targeted manner, and anemia can be effectively corrected. Through high-activity component targeting, multi-effect synergistic conditioning and safe process guarantee, side effects and dependency of western medicines are avoided, technical shortages of traditional products are made up, a safe, efficient and accurate conditioning scheme is provided for women with premature ovarian failure, clinical application value and industrial transformation potential are both achieved, and the pharmaceutical composition is worthy of popularization and application. The policy orientation of high-quality development of medicinal and edible functional foods is met.

Provided is a composition that includes an extract from seaweed and has excellent action and efficacy. This composition is characterized by including extracellular vesicles (EVs) and carotenoids.

The invention discloses a fluorescent probe for cAMP transport dynamic visual detection and efficient inhibitor screening, the fluorescent probe comprises cAMP as a targeting unit and jatrorrhizine hydrochloride as a fluorophore, and the jatrorrhizine hydrochloride and the cAMP are connected through flexible molecules; the fluorescent probe has good water solubility and aggregation-induced emission (AIE) characteristics, has high sensitivity and stability, can detect the process of transmembrane protein transport cAMP (cyclic adenosine monophosphate) in real time, rapidly and highly sensitively, and is especially suitable for the SLCO4C1 membrane protein mediated cAMP (cyclic adenosine monophosphate) transport process, thereby realizing visual fluorescence monitoring of the transport process. And meanwhile, the method can also be used for screening proteins interacting with cAMP, such as a PDE protein inhibitor.

The invention relates to the technical field of component detection, in particular to a method for detecting insomnia treatment components of semen ziziphi spinosae with shells, and the method comprises the steps of component identification, insomnia component research and experimental result analysis. Comprising the following steps: carrying out comprehensive characterization on chemical components of shell spina date seed powder by adopting an ultra-high performance liquid chromatography-quadrupole rod-electrostatic field orbitrap coupling technology to obtain a total ion chromatogram; the method comprises the following steps: constructing a wild jujube chemical component information database according to a TCMSP database, a Chemspider database, a PubChem database and related literature data; by utilizing Xcalibur software, the network diagram drawn by the method visually shows the incidence relation between different components in the spina date seeds and anti-insomnia targets and diseases, possible main active components such as cyclic adenosine monophosphate and lysimachimine are determined through network topology analysis, and a clear active component clue is provided for research and development of medicines based on the spina date seeds.

The invention relates to the technical field of biological medicines, in particular to a method for inducing neural stem cells to differentiate into dopaminergic neurons by a small molecule compound. A magnetic mesoporous silica-phase change liposome composite system is constructed, wherein the surface of a three-dimensional porous bioglass substrate is modified with bifunctional peptide, and a glycogen synthase kinase inhibitor, a transmembrane protease inhibitor and a bone morphogenetic protein receptor antagonist are loaded on the three-dimensional porous bioglass substrate. A response mechanism of a photosensitive cyclic adenylate analogue and a dopamine synthesis precursor is activated through blue light pulses, and finally targeted sorting is completed by a fluorescent tracing substrate, so that a high-purity functional dopaminergic neuron population is obtained. Through physical microenvironment optimization, chemical signal channel regulation and control and multi-dimensional integration of a light-operated maturation mechanism, efficient and controllable differentiation of neural stem cells to dopaminergic neurons is realized, and a standardized preparation scheme is provided for Parkinson's disease cell therapy.

The application relates to the field of biological technology, in particular to application of cyclic adenosine monophosphate in promoting biomass increase of pasture and root nodule, wherein the cyclic adenosine monophosphate significantly improves the fresh weight biomass of the above-ground part, the root part and the single-plant root system root nodule of Medicago truncatula inoculated with rhizobium, and the difference is significant.

The invention relates to an application of tolvaptan as an active ingredient in preparation of a medicine or a medical beauty product for inhibiting melanin synthesis. Cell activity detection and melanin content determination show that the tolvaptan can significantly reduce the melanin content in cells without affecting the cell activity. Tyrosinase activity detection shows that tolvaptan does not affect the catalytic activity of TYR. Protein immunoblotting experiments show that tolvaptan can down-regulate the expression levels of TYR family proteins, ommatidium-associated transcription factors (MITF), cyclic adenylate reaction element binding proteins (CREB) and melanocortin-1 receptors (MC1R).

This invention discloses a method for preparing a molecularly imprinted electrochemical sensor for detecting cyclic adenosine monophosphate (cAMP). The sensor uses reduced graphene oxide (RGO) and gold nanoparticles as modifying materials. RGO is drop-coated onto the surface of a glassy carbon electrode and dried to obtain a modified electrode RGO / GCE. The RGO / GCE is then placed in a sulfuric acid deposition solution containing chloroauric acid, and gold nanoparticles are used to modify the RGO / GCE surface using a potentiostatic method to form a gold substrate, resulting in a deposited electrode AuNPs / RGO / GCE. The AuNPs / RGO / GCE is then electropolymerized in an electrolyte polymerization solution containing the template substance cAMP and the functional monomer o-phenylenediamine to obtain a dense and insulating polymer film. The polymerized electrode is immersed in an elution solution and eluted using cyclic voltammetry to obtain MIP / AuNPs / RGO / GCE. This sensor exhibits specific recognition selectivity for cAMP, high detection sensitivity, low detection limit, good reusability, and stability.

The present disclosure is directed to methods (e.g., in vitro methods) for detecting the presence of neutralizing antibodies to PTH or PTHrP analog in a sample. The in vitro method comprises the steps of obtaining a sample from a subject; contacting the sample with a cell; measuring cyclic adenosine monophosphate (cAMP) levels; and detecting the presence of neutralizing antibodies, when cAMP levels are reduced relative to a negative control sample without neutralizing antibodies. An in vitro method of detecting the presence of neutralizing antibodies in a sample from a subject treated with Abaloparatide is also provided. Further provided herein is a kit for carrying out the methods described herein comprising components required to carry out the obtaining, contacting, measuring and detecting steps and instructions for use.

The present application relates to the technical field of diagnosis markers and diagnosis methods for mental illness of children and adolescents, in particular to a plasma metabolic diagnosis marker and a diagnosis system for depression of children and adolescents. The plasma metabolic diagnosis marker comprises at least one of cyclic adenosine monophosphate, methylpyridine, unsaturated undecylenoyl carnitine, histidinol, prolyl hydroxyproline, tryptophan and glucuronic acid. The present application analyzes non-target metabolomics data, and determines seven candidate diagnosis markers for depression of children and adolescents from common differential metabolites. Then, through targeted metabolomics research, diagnosis markers and their combinations with ideal diagnosis effects are determined, and a diagnosis model is constructed. The gender factor is also included in the diagnosis model to further improve the diagnosis effect. The present application can solve the technical problem that the reliability and promotion potential of the plasma metabolic biomarkers for depression of children and adolescents in the prior art are not ideal, and has an ideal promotion and application prospect.

The present disclosure is directed to methods (e.g., in vitro methods) for detecting the presence of neutralizing antibodies to PTH or PTHrP analog in a sample. The in vitro method comprises the steps of obtaining a sample from a subject; contacting the sample with a cell; measuring cyclic adenosine monophosphate (cAMP) levels; and detecting the presence of neutralizing antibodies, when cAMP levels are reduced relative to a negative control sample without neutralizing antibodies. An in vitro method of detecting the presence of neutralizing antibodies in a sample from a subject treated with Abaloparatide is also provided. Further provided herein is a kit for carrying out the methods described herein comprising components required to carry out the obtaining, contacting, measuring and detecting steps and instructions for use.

The present application relates to a kind of traditional Chinese medicine composition for treating ischemic heart failure and preparation method thereof, belong to the field of traditional Chinese medicine pharmacy, the traditional Chinese medicine composition includes: cassia 5-15 parts, white atractylodes 5-15 parts, poria 5-15 parts, dried ginger 6-12 parts, acanthopanax 5-15 parts, water red flower seed 10-30 parts, verbena 3-9 parts, dogwood 6-12 parts, fried licorice 3-9 parts.The composition can significantly reduce N-terminal B-type natriuretic peptide level, significantly improve model rat heart tissue pathological changes, regulate the heart function of model rat, improve the systolic function of heart, and can reduce the expression of rat interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha and other inflammatory factors, involve extracellular matrix receptor interaction, chemotactic factor signal pathway, relaxin signal pathway, cyclic adenosine monophosphate signal pathway, nuclear factor-kappa B signal pathway and multiple pathways, and is effective drug for treating ischemic heart failure.

This invention discloses a type of Lactobacillus paracasei ( Lactobacillus paracasei Preparation of Lactobacillus paracasei F5 and polysaccharide synbiotic composition and its application in alleviating behavioral cognitive impairment in the elderly. This strain is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 35145, dated July 9, 2025. The synbiotic composition consists of lyophilized Lactobacillus paracasei F5 powder and arabinoxylan (AX) or galactooligosaccharides (GOS) in a specific mass ratio, with a viable count ≥ 1 × 10⁻⁶. 8 CFU / g. In an Aβ transgenic fruit fly model, administration of the synbiotic for 8 consecutive days significantly improved the climbing ability of the model fruit flies and reduced Aβ levels in the brain. 42 Levels of AChE and cyclic adenosine monophosphate (cAMP) were observed. In a mouse model induced by AlCl3 combined with D-gal, continuous gavage for 11 weeks significantly reversed learning and memory deficits and downregulated Aβ levels in the hippocampus. 42 This study aims to reduce the deposition and AChE activity of pro-inflammatory factors in the cerebral cortex, providing a safe and feasible strategy for dietary intervention in cognitive impairment in the elderly, with broad application prospects.